Chrysalis Study
About NSCLC &
Biomarkers
About NSCLC
About Biomarkers
Understanding Biomarkers Why Get Tested FAQs
About Clinical
Research Studies
Understanding Clinical Research Why Participate FAQs
Current Clinical
Research Studies
Current Studies
Chrysalis Study Chrysalis 2 Study Mariposa 2 Study Papillon Study
Study Locations
Participating Countries
For Healthcare
Providers
For Caregivers &
Loved Ones
Additional
Resources
NSCLC Support Janssen Oncology Research
EN-US
ES-US EN-AU
See If You Are Eligible
1-855-218-4395

About The Chrysalis Study

The CHRYSALIS Study is evaluating the safety and effectiveness of one investigational medication or a combination of two investigational medications. The study includes multiple groups of people with different types of non-small-cell lung cancer (NSCLC) . These groups may not all be recruiting new participants at the same time.

The MET Exon 14 Skipping Group is open for enrollment
Participants in this group need to have been diagnosed with NSCLC that has spread (metastatic) or cannot be removed by surgery (unresectable),with a primary gene mutation called a MET Exon 14 skipping mutation. Participants in this group will receive one investigational medication.

See If You Are Eligible

The Wild Type (WT) Group is open for enrollment
Participants in this group need to have been diagnosed with NSCLC types known as adenocarcinoma or squamous cell carcinoma and have disease that has progressed on prior chemotherapy and immunotherapy. Tumor testing needs to be negative for certain gene mutations (EGFR and ALK), and special testing will be done to see if the tumor has proteins known as EGFR and/or MET.

You may be able to take part in the CHRYSALIS Study if you:

  • Are 18 years or older
  • Have been diagnosed with advanced or unresectable NSCLC
  • Have received prior treatment, which was not effective, or are ineligible for other currently available treatments
  • Are either fully active and able to carry on all physical activities, or are restricted in strenuous activity, but can walk around and carry out light housework or office work
  • For the MET Exon Skipping Group: have been diagnosed with a primary MET Exon 14 skipping mutation in the lung cancer
  • For the WT Group: have EGFR and/or MET proteins in the lung cancer
Additional eligibility criteria will be assessed by the study doctor or staff.

See If You Are Eligible

For additional information:

Download the CHRYSALIS Fact Sheet
What can I expect if I join the study?

Participants in the CHRYSALIS Study will receive the investigational medication or combination of investigational medications while completing various study tests and procedures.

  • The study duration will vary from person to person depending on the response to the investigational medication
  • Dosing will take place once a week for the first four weeks of study medication cycle 1, and then every other week for the rest of the study
  • Each study medication cycle will last 28 days
  • Participants may leave the study at any point in time
Does participating in this study cost me anything?

All study-required visits, tests, and medications will be provided at no cost to qualified participants. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine. In addition, reimbursement for study-required travel, meals, and parking may be available.

If pre-qualified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

  • Learn more about the CHRYSALIS Study. You’ll be speaking with a study doctor at the study clinic to learn more regarding your participation in this study.
  • Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.
  • Determine if the CHRYSALIS Study may be right for you. After speaking with the study doctor and learning details about this study, the study staff will perform a series of screening tests to determine if you are eligible to participate. If you are eligible, you and your doctor can then decide if this study is right for you. No tests for the actual study will be given at this time. If you agree to take part, the study staff will ask you to review and sign a consent form.
What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, your study doctor will ask you to come to the study clinic for further evaluation. If your disease is progressing, you can discuss options with your study doctor. You will then enter the follow-up phase with visits to the study clinic or telephone contact every 12 weeks until the end of the study to find out how you are doing, if you have had any side effects, and if you have started any new cancer treatments.

Where are the study clinics located?

There are study clinics located throughout the world.

Within the United States: to find a location near you, visit this page.

Other participating countries: there are study clinics in over 11 countries globally—to find a location near you, visit this page.

For additional information:

Download the CHRYSALIS Fact Sheet
Consider enrolling in this study today.
See If You Are Eligible

SOURCE:

1ecog-acrin.org/resources/ecog-performance-status
If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path.

The more we learn, the farther we can go.

See If You Are Eligible